Enhanced neutrophil functions by recombinant human granulocyte colony-stimulating factor in diabetic patients with foot infections in vitro

被引:26
作者
Peck, KR
Son, DW
Song, JH
Kim, S
Oh, MD
Choe, KW
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Infect Dis,Kangnam Gu, Seoul 135710, South Korea
[2] Eulji Univ, Sch Med, Nowon Hosp, Eulji Med Ctr,Dept Pediatr, Seoul, South Korea
[3] Seoul Natl Univ, Coll Med, Div Infect Dis, Seoul, South Korea
关键词
diabetes mellitus; neutrophils; granulocyte colony-stimulating factor; phagocytosis; superoxides;
D O I
10.3346/jkms.2001.16.1.39
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study was performed to evaluate the effect of granulocyte-colony stimulating factor on neutrophil functions in diabetic patients with active foot infections in vitro. Twelve diabetic patients with foot infections and 12 normal volunteers were enrolled. Neutrophils from peripheral blood were incubated with granulocyte colony-stimulating factor (G-CSF, 50 ng/ml) for 20 min. Superoxide production of neutrophils was measured by the reduction of ferricytochrome C. Neutrophil phagocytosis was assayed using Staphylococcus aureus and the weighted phagocytic index was calculated. Superoxide production of neutrophils in diabetic patients with foot infections was 7.7 (unit: nmol/2 x 10(5) cells/60 min), which was significantly lower than that in controls (12.0) (p<0.05). G-CSF increased neutrophil superoxide production to 12.1 in diabetic patients with foot infections and to 19.8 in controls (p<0.05 for each). Weighted phagocytic index in diabetic patients with foot infections was 0.77, which was not significantly different from that of the controls (0.69). Weighted phagocytic index was increased significantly by G-CSF to 0.88 in diabetic patients with foot infections and to 0.79 in controls (p<0.05 for each). In conclusion, G-CSF significantly enhanced neutrophil functions in diabetic patients with foot infections in vitro.
引用
收藏
页码:39 / 44
页数:6
相关论文
共 39 条
[1]   EFFECTS OF GRANULOCYTE COLONY-STIMULATING FACTOR IN MODIFYING MORTALITY FROM PSEUDOMONAS-AERUGINOSA PNEUMONIA AFTER HEMORRHAGE [J].
ABRAHAM, E ;
STEVENS, P .
CRITICAL CARE MEDICINE, 1992, 20 (08) :1127-1133
[2]   DIABETIC FOOT INFECTIONS - PATHOPHYSIOLOGY AND TREATMENT [J].
BRIDGES, RM ;
DEITCH, EA .
SURGICAL CLINICS OF NORTH AMERICA, 1994, 74 (03) :537-555
[3]   PROPHYLACTIC OR SIMULTANEOUS ADMINISTRATION OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR IN THE TREATMENT OF GROUP-B STREPTOCOCCAL SEPSIS IN NEONATAL RATS [J].
CAIRO, MS ;
MAUSS, D ;
KOMMAREDDY, S ;
NORRIS, K ;
VANDEVEN, C ;
MODANLOU, H .
PEDIATRIC RESEARCH, 1990, 27 (06) :612-616
[4]  
CAIRO MS, 1990, BLOOD, V76, P1788
[5]   Neutrophil transfusions: kinetics and functions of neutrophils mobilized with granulocyte-colony-stimulating factor and dexamethasone [J].
Dale, DC ;
Liles, WC ;
Llewellyn, C ;
Rodger, E ;
Price, TH .
TRANSFUSION, 1998, 38 (08) :713-721
[6]   DEFECTIVE PHAGOCYTOSIS IN INSULIN CONTROLLED DIABETICS - EVIDENCE FOR A REACTION BETWEEN GLUCOSE AND OPSONIZING PROTEINS [J].
DAVIDSON, NJ ;
SOWDEN, JM ;
FLETCHER, J .
JOURNAL OF CLINICAL PATHOLOGY, 1984, 37 (07) :783-786
[7]   Phase 1 safety trial of Filgrastim (r-metHuG-CSF) in non-neutropenic patients with severe community-acquired pneumonia [J].
deBoisblanc, BP ;
Mason, CM ;
Andresen, J ;
Logan, E ;
Bear, MB ;
Johnson, S ;
Shellito, J ;
Summer, WR ;
Nelson, S .
RESPIRATORY MEDICINE, 1997, 91 (07) :387-394
[8]  
Delamaire M, 1997, DIABETIC MED, V14, P29, DOI 10.1002/(SICI)1096-9136(199701)14:1<29::AID-DIA300>3.0.CO
[9]  
2-V
[10]   PHAGOCYTIC AND BACTERICIDAL ACTIVITY OF GRANULOCYTES IN DIABETIC CHILDREN [J].
DZIATKOWIAK, H ;
KOWALSKA, M ;
DENYS, A .
DIABETES, 1982, 31 (12) :1041-1043